FDA Inspection 1235365 — Clario Inc.
The FDA completed an inspection of Clario Inc. on March 22, 2024 in Philadelphia, PA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- March 22, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Philadelphia, PA (United States)
Additional Details
Sponsor, Contract Research Organization